Procalcitonin Use in Pneumonia Patients in the Critical Care Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01788488|
Recruitment Status : Completed
First Posted : February 11, 2013
Last Update Posted : June 25, 2013
|Condition or disease||Intervention/treatment||Phase|
|Pneumonia||Other: Use of procalcitonin as biomarker to guide therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||134 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Impact of Measuring Serum Procalcitonin Levels on Duration of Antimicrobial Therapy in Critical Care Patients With Suspected Pneumonia|
|Study Start Date :||February 2013|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||June 2013|
|No Intervention: Standard Therapy|
Experimental: Procalcitonin-guided therapy
Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
Other: Use of procalcitonin as biomarker to guide therapy
- Length of antibiotic therapy [ Time Frame: Indefinite ]Participants will be followed for the entire time they are on antibiotics to treat pneumonia, an expected average of 30 total antibiotic days.
- Length of stay in critical care unit [ Time Frame: Indefinite ]Participants will be followed for their entire length of stay in the critical care unit, an expected average of 7 days.
- Cost [ Time Frame: Once ]The average cost of antibiotics per patient, measured in US dollars, based on total antibiotic days.
- Length of stay in the hospital [ Time Frame: Indefinite ]Participants will be followed their entire length of stay in the hospital, an expected average of 14 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01788488
|United States, Wisconsin|
|Mayo Clinic Health System Eau Claire|
|Eau Claire, Wisconsin, United States, 54702|
|Principal Investigator:||Kent Gierhart||Mayo Clinic|